SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about record date

24 Aug 2018 Evaluate

Pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that the Board of Directors has fixed Thursday, 13th September, 2018 as the Record Date for determining the entitlement of members to receive Bonus Shares. The Bonus Shares, once allotted, shall rank pari-passu in all respects with and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new Equity Shares are allotted.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2491.40 28.65 (1.16%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×